We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Teladoc (TDOC - Free Report) closed the most recent trading day at $25.87, moving +1.09% from the previous trading session. This change outpaced the S&P 500's 0.33% gain on the day. Elsewhere, the Dow gained 0.3%, while the tech-heavy Nasdaq added 1.92%.
Prior to today's trading, shares of the telehealth services provider had gained 4.15% over the past month. This has lagged the Medical sector's gain of 5.81% and the S&P 500's gain of 5.67% in that time.
Investors will be hoping for strength from Teladoc as it approaches its next earnings release, which is expected to be April 26, 2023. The company is expected to report EPS of -$0.50, down 6.38% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $617.47 million, up 9.22% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.41 per share and revenue of $2.6 billion, which would represent changes of +98.33% and +7.89%, respectively, from the prior year.
Any recent changes to analyst estimates for Teladoc should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Teladoc is holding a Zacks Rank of #3 (Hold) right now.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know
Teladoc (TDOC - Free Report) closed the most recent trading day at $25.87, moving +1.09% from the previous trading session. This change outpaced the S&P 500's 0.33% gain on the day. Elsewhere, the Dow gained 0.3%, while the tech-heavy Nasdaq added 1.92%.
Prior to today's trading, shares of the telehealth services provider had gained 4.15% over the past month. This has lagged the Medical sector's gain of 5.81% and the S&P 500's gain of 5.67% in that time.
Investors will be hoping for strength from Teladoc as it approaches its next earnings release, which is expected to be April 26, 2023. The company is expected to report EPS of -$0.50, down 6.38% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $617.47 million, up 9.22% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.41 per share and revenue of $2.6 billion, which would represent changes of +98.33% and +7.89%, respectively, from the prior year.
Any recent changes to analyst estimates for Teladoc should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Teladoc is holding a Zacks Rank of #3 (Hold) right now.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.